HU205010B - Process for producing pharmaceutical compositions comprising compounds soluble up to 1 per cent and having medical activity - Google Patents

Process for producing pharmaceutical compositions comprising compounds soluble up to 1 per cent and having medical activity Download PDF

Info

Publication number
HU205010B
HU205010B HU884518A HU451888A HU205010B HU 205010 B HU205010 B HU 205010B HU 884518 A HU884518 A HU 884518A HU 451888 A HU451888 A HU 451888A HU 205010 B HU205010 B HU 205010B
Authority
HU
Hungary
Prior art keywords
component
water
monoester
september
priority
Prior art date
Application number
HU884518A
Other languages
English (en)
Hungarian (hu)
Other versions
HUT49494A (en
Inventor
Lorenz Hahn
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz Ag filed Critical Sandoz Ag
Publication of HUT49494A publication Critical patent/HUT49494A/hu
Publication of HU205010B publication Critical patent/HU205010B/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HU884518A 1987-09-15 1988-09-01 Process for producing pharmaceutical compositions comprising compounds soluble up to 1 per cent and having medical activity HU205010B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3730909 1987-09-15
DE3802355 1988-01-27

Publications (2)

Publication Number Publication Date
HUT49494A HUT49494A (en) 1989-10-30
HU205010B true HU205010B (en) 1992-03-30

Family

ID=25859774

Family Applications (1)

Application Number Title Priority Date Filing Date
HU884518A HU205010B (en) 1987-09-15 1988-09-01 Process for producing pharmaceutical compositions comprising compounds soluble up to 1 per cent and having medical activity

Country Status (24)

Country Link
JP (1) JP3090666B2 (ja)
KR (1) KR0131084B1 (ja)
AT (1) AT395819B (ja)
AU (1) AU628787B2 (ja)
BE (1) BE1001204A5 (ja)
CA (1) CA1338775C (ja)
CH (1) CH683672A5 (ja)
DK (1) DK175132B1 (ja)
ES (1) ES2012118A6 (ja)
FI (1) FI94837C (ja)
FR (1) FR2620336B1 (ja)
GB (1) GB2209671B (ja)
GR (1) GR1002243B (ja)
HU (1) HU205010B (ja)
IE (1) IE61195B1 (ja)
IL (1) IL87746A (ja)
IT (1) IT1224886B (ja)
LU (1) LU87335A1 (ja)
MY (1) MY103769A (ja)
NL (1) NL195094C (ja)
NO (1) NO179434C (ja)
NZ (1) NZ226163A (ja)
PT (1) PT88492B (ja)
SE (1) SE503279C2 (ja)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2222770B (en) * 1988-09-16 1992-07-29 Sandoz Ltd Pharmaceutical compositions containing cyclosporins
US6007840A (en) * 1988-09-16 1999-12-28 Novartis Ag Pharmaceutical compositions comprising cyclosporins
GR1000466B (el) * 1989-01-28 1992-07-30 Sandoz Ag Μεθοδος παρασκευης νεων φαρμακευτικων μορφων κυκλοσπορινης.
BE1003009A5 (fr) * 1989-02-09 1991-10-22 Sandoz Sa Nouvelles compositions pharmaceutiques a base de cyclosporines.
GB8916901D0 (en) 1989-07-24 1989-09-06 Sandoz Ltd Improvements in or relating to organic compounds
US6262022B1 (en) 1992-06-25 2001-07-17 Novartis Ag Pharmaceutical compositions containing cyclosporin as the active agent
EP0642332B1 (en) 1992-05-13 1997-01-15 Sandoz Ltd. Ophthalmic compositions containing a cyclosporin
EP1142568A1 (en) 1992-09-25 2001-10-10 Novartis AG Pharmaceutical compositions containing cyclosporins
SI1033128T2 (sl) 1993-09-28 2012-02-29 Scherer Gmbh R P Izdelava mehke Ĺľelatinaste kapsule
RU2158601C2 (ru) 1994-11-03 2000-11-10 Новартис Аг Новые лекарственные формы циклоспорина для орального применения с простым составом и высокой биодоступностью и способ их получения
US5834017A (en) * 1995-08-25 1998-11-10 Sangstat Medical Corporation Oral cyclopsporin formulations
US5766629A (en) * 1995-08-25 1998-06-16 Sangstat Medical Corporation Oral cyclosporin formulations
US5827822A (en) * 1996-03-25 1998-10-27 Sangstat Medical Corporation Cyclosporin a formulations as nanoparticles
US5962019A (en) * 1995-08-25 1999-10-05 Sangstat Medical Corporation Oral cyclosporin formulations
DE19549852B4 (de) 1995-11-29 2009-06-04 Novartis Ag Cyclosporin enthaltende Präparate
TW414696B (en) * 1996-07-01 2000-12-11 Mitsubishi Kagaku Foods Kk Anti-bacteria agent
SK285019B6 (sk) 1997-01-30 2006-04-06 Novartis Ag Tvrdá želatínová tobolka
GB2326337A (en) * 1997-06-20 1998-12-23 Phares Pharma Holland Homogeneous lipid compositions for drug delivery
US7732404B2 (en) 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
EP1558215A4 (en) * 2003-10-14 2007-09-12 Wockhardt Ltd STERILE GELIFYING AGENTS
JP5422871B2 (ja) * 2006-10-24 2014-02-19 不二製油株式会社 イソフラボン類組成物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL284933A (ja) * 1961-10-31
GB1134878A (en) * 1966-05-12 1968-11-27 Suga Kazuo Improvements in and relating to oryzanol solutions and compositions
FR5986M (ja) * 1966-11-22 1968-06-21
BE787842A (fr) * 1971-08-25 1972-12-18 Sumito Chemical Cy Ltd Procede de preparation d'une suspension aqueuse de cristaux stables du type non beta d'esters d'acides gras superieurs du chloramphenicol
JPS53107408A (en) * 1977-02-28 1978-09-19 Yamanouchi Pharmaceut Co Ltd Micellar preparation for rectal infusion
FI65914C (fi) * 1978-03-07 1984-08-10 Sandoz Ag Foerfarande foer framstaellning av farmaceutiska kompositionerinnehaollande cyklosporin a
JPS57128634A (en) * 1981-02-03 1982-08-10 Eisai Co Ltd Elastase-containing compound increasing absorption
EP0179583A1 (en) * 1984-10-04 1986-04-30 Merck & Co. Inc. A system for enhancing the water dissolution rate and solubility of poorly soluble drugs
JPS61280435A (ja) * 1985-04-04 1986-12-11 Kanji Takada サイクロスポリン類のリンパ指向性製剤

Also Published As

Publication number Publication date
GR880100602A (el) 1989-06-22
AU2217288A (en) 1989-04-27
NL8802275A (nl) 1989-04-03
PT88492B (pt) 1993-03-31
FI94837B (fi) 1995-07-31
DK511188D0 (da) 1988-09-14
FI94837C (fi) 1995-11-10
ES2012118A6 (es) 1990-03-01
GB2209671A (en) 1989-05-24
AT395819B (de) 1993-03-25
FR2620336B1 (fr) 1991-10-25
NO179434B (no) 1996-07-01
IL87746A0 (en) 1989-02-28
GB8821443D0 (en) 1988-10-12
GR1002243B (en) 1996-04-22
CH683672A5 (de) 1994-04-29
IL87746A (en) 1992-07-15
LU87335A1 (fr) 1989-04-06
IE61195B1 (en) 1994-10-19
NO179434C (no) 1996-10-09
IE882772L (en) 1989-03-15
KR0131084B1 (ko) 1998-04-17
SE8803221L (sv) 1989-03-16
HUT49494A (en) 1989-10-30
JP3090666B2 (ja) 2000-09-25
KR890004694A (ko) 1989-05-09
NL195094C (nl) 2003-12-17
SE8803221D0 (sv) 1988-09-13
CA1338775C (en) 1996-12-10
PT88492A (pt) 1988-10-01
AU628787B2 (en) 1992-09-24
DK175132B1 (da) 2004-06-14
DK511188A (da) 1989-03-16
FI884192A0 (fi) 1988-09-13
IT1224886B (it) 1990-10-24
ATA224988A (de) 1992-08-15
NO884052L (no) 1989-03-16
NO884052D0 (no) 1988-09-13
GB2209671B (en) 1991-11-13
BE1001204A5 (fr) 1989-08-16
FR2620336A1 (fr) 1989-03-17
IT8848349A0 (it) 1988-09-14
SE503279C2 (sv) 1996-05-13
MY103769A (en) 1993-09-30
NZ226163A (en) 1991-08-27
JPH01151526A (ja) 1989-06-14
FI884192A (fi) 1989-03-16

Similar Documents

Publication Publication Date Title
HU205010B (en) Process for producing pharmaceutical compositions comprising compounds soluble up to 1 per cent and having medical activity
US5756450A (en) Water soluble monoesters as solubilisers for pharmacologically active compounds and pharmaceutical excipients and novel cyclosporin galenic forms
KR100188305B1 (ko) 신규의 시클로스포린 결정 형태, 이것의 제조 방법 및 이것을 함유한 약학 조성물 및 그 용도
JP4073503B2 (ja) サイクロスポリンを含有する液体製剤とその調製方法
EP0874621B1 (en) [3'-DESOXY-3-OXO-MeBmT]1-[Val]2-CICLOSPORIN-CONTAINING EMULSION PHARMACEUTICAL COMPOSITIONS
JP2003534265A (ja) 生物学的に活性な親水性化合物を非経口的に投与するための徐放性薬剤組成物
PL183579B1 (pl) Preparat doustny cyklosporyny o wysokiej dostępności biologicznej oraz sposób wytwarzania preparatu doustnego cyklosporyny o wysokiej dostępności biologicznej
HUT73664A (en) Pharmaceutically acceptable improved compositions containing an alcohol and a hydrophobic drug
JPH0611703B2 (ja) 新規シクロスポリン製剤
JP2003507343A (ja) 経口及び局所投与用の医薬組成物
EP1151755B1 (en) Pharmaceutical compositions comprising cyclosporin as active ingredient
DE3830494B4 (de) Wasserlösliche Monoester als Solubilisatoren für pharmakologische Wirkstoffe und pharmazeutische Hilfsstoffe
WO2010141068A1 (en) Opthalmic compositions of cyclosporin
KR0173349B1 (ko) 사이클로스포린-함유 고체 분산체 조성물
AU3043400A (en) Cyclosporin solution
MXPA97000019A (en) New formulations to prepare the cyclosporine for oral administration with a simple composition and high biodisponibility, and procedure for its manufacture

Legal Events

Date Code Title Description
HPC4 Succession in title of patentee

Owner name: NOVARTIS A.G., CH